News

Article

Recipharm Acquires Portuguese CDMO, GenIbet, Boosting Biologics Offering

Recipharm will build up its biologics service offering with the acquisition of GenIbet.

On Feb. 1, 2022, Recipharm announced the acquisition of GenIbet, a Portuguese contract development and manufacturing organization specializing in clinical trial manufacturing and the manufacture of novel modalities, including viral vectors, RNA, and microbiome. The acquisition bolsters Recipharm’s biologics offering, specifically drug substance manufacturing of novel advanced therapy medicinal products.

GenIbet currently focuses on the preclinical and Phase I stages and offers process development services, including the development of new production routes not previously established. Under the deal, Genlbet will provide Recipharm with a platform from which to build its capabilities in new biologics modalities.

“This acquisition is an important step for us in growing our biologics business. We look forward to working closely with the GenIbet team, building links across the wider Recipharm organization to make this business a huge success,” said Marc Funk, CEO of Recipharm, in a company press release.

“Combining our experience and expertise with Recipharm’s capabilities and market reach will make a significant difference for customers on an international scale,” said Raquel Fortunato, CEO at GenIbet, in the press release.

Source: Recipharm

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content